

10. Italiani P, Manca M, Angelotti F, et al. IL-1 family cytokines and soluble receptors in systemic lupus erythematosus. *Arthritis Res Ther.* 2018;20:27.
11. Suh CH, Kim SS, Hong SJ, et al. Novel diagnostic biomarker of systemic lupus erythematosus – antichaperonin containing T-complex peptide 1 antibody. *J Rheumatol.* 2025;52(Suppl 1):99-100.
12. Fanouriakis A, Kostopoulou M, Andersen J, et al. EULAR recommendations for the management of systemic lupus erythematosus: 2023 update. *Ann Rheum Dis.* 2024;83:15-29.
13. Kidney Disease: Improving Global Outcomes (KDIGO) Lupus Nephritis Work Group. KDIGO 2024 Clinical Practice Guideline for the Management of Lupus Nephritis. *Kidney Int.* 2024;105(1S):S1-S69.
14. Horák P. Principy léčby SLE dle aktualizovaných doporučení EULAR 2023 – komentář. *Čes Revmatol.* 2024;32(3):107-115.
15. www.sukl.cz. Available from: <https://www.sukl.cz>
16. Wallace DJ, Stohl W, Furie RA, et al. A phase II, randomized, double-blind, placebo-controlled, dose-ranging study of belimumab in patients with active systemic lupus erythematosus. *Arthritis Care Res.* 2009;61:1168-1178.
17. Furie R, Petri M, Zamani O, et al. A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus. *Arthritis Rheum.* 2011;63:3918-3930.
18. Navarra SV, Guzman RM, Gallacher AE, et al. Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial. *Lancet.* 2011;377:721-731.
19. Stohl W, Schwarting A, Okada M, et al. Efficacy and safety of subcutaneous belimumab in systemic lupus erythematosus: a fifty-two-week randomized, double-blind placebo-controlled study. *Arthritis Rheumatol.* 2017;69:1016-1027.
20. Zhang F, Bae SC, Bass D, et al. A pivotal phase III, randomised, placebo-controlled study of belimumab in patients with systemic lupus erythematosus located in China, Japan and South Korea. *Ann Rheum Dis.* 2018;77:355-363.
21. Furie R, Rovin BH, Houssiau F, et al. Two-year, randomized, controlled trial of Belimumab in lupus nephritis. *N Engl J Med.* 2020;383:1117-28.
22. Atisha-Fregoso Y, Malkiel S, Harris KM, et al. Phase II Randomized Trial of Rituximab Plus Cyclophosphamide Followed by Belimumab for the Treatment of Lupus Nephritis. *Arthritis Rheumatol Hoboken NJ.* <https://doi.org/10.1002/art.41466>. Epub ahead of print 4 August 2020.
23. Furie R, Khamashta M, Merrill JT, et al. Anifrolumab, an Anti-Interferon- α Receptor Monoclonal Antibody, in moderate-to-severe systemic lupus erythematosus: Anifrolumab in moderate-to-severe SLE. *Arthritis Rheumatol.* 2017;69:376-86.
24. Furie RA, Morand EF, Bruce IN, et al. Type I interferon inhibitor anifrolumab in active systemic lupus erythematosus (TULIP-1): a randomised, controlled, phase 3 trial. *Lancet Rheumatol.* 2019;1:e208-19.
25. Morand EF, Furie R, Tanaka Y, et al. Trial of Anifrolumab in active systemic lupus erythematosus. *N Engl J Med.* 2020;382:211-21.
26. Jayne D, Rovin B, Mysler F, et al. Phase II randomised trial of type I interferon inhibitor anifrolumab in patients with active lupus nephritis. *Ann Rheum Dis.* 2022;81:496-506.
27. Merrill JT, Neuwelt CM, Wallace DJ et al. Efficacy and safety of rituximab in moderately- to -severely active systemic lupus erythematosus: the randomized, double-blind, phase II/III systemic lupus erythematosus evaluation of rituximab trial. *Arthritis Rheum.* 2010 Jan;62(1):222-33.
28. Rovin BH, Furie R, Latinis K, et al. Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the Lupus Nephritis Assessment with Rituximab study. *Arthritis Rheum.* 2012 Apr;64(4):1215-26. doi: 10.1002/art.34359. Epub 2012 Jan 9. PMID: 22231479.
29. Gomez Mendez LM, Cascino MD, Garg J, et al. Peripheral blood B cell depletion after rituximab and complete response in lupus nephritis. *Clin J Am Soc Nephrol.* 2018;13:1502-9.
30. Kalunian KC, Merrill JT, Maciuga R, et al. A phase II study of the efficacy and safety of roplizumab (rhuMAB interferon- α) in patients with systemic lupus erythematosus (ROSE). *Ann Rheum Dis.* 2016;75:196-202.
31. Khamashta M, Merrill JT, Werth VP, et al. Sifalimumab, an anti-interferon- α monoclonal antibody, in moderate to severe systemic lupus erythematosus: a randomised, double-blind, placebo-controlled study. *Ann Rheum Dis.* 2016;75:1909-1916.
32. Furie R, Dooley MA, Wofsy D, et al. A phase III randomised, double-blind, placebo-controlled study to evaluate the efficacy and safety of abatacept or placebo on standard of care in patients with active class III or IV lupus nephritis. *Ann Rheum Dis.* 2018;77:176-177.
33. Furie RA, Leon G, Thomas M, et al. A phase 2, randomised, placebo-controlled clinical trial of blisibimod, an inhibitor of B cell activating factor, in patients with moderate-to-severe systemic lupus erythematosus, the PEARL-SC study. *Ann Rheum Dis.* 2015;74:1667-1675.
34. Merrill JT, Shanahan WR, Scheinberg M, et al. Phase III trial results with blisibimod, a selective inhibitor of B-cell activating factor, in subjects with systemic lupus erythematosus (SLE): results from a randomised, double-blind, placebo-controlled trial. *Ann Rheum Dis.* 2018;77:883-889.
35. Isenberg DA, Petri M, Kalunian K, et al. Efficacy and safety of subcutaneous tabalumab in patients with systemic lupus erythematosus: results from ILLUMINATE-1, a 52-week, phase III, multicentre, randomised, double-blind, placebo-controlled study. *Ann Rheum Dis.* 2016;75:323-331.
36. Merrill JT, van Vollenhoven RF, Buyon JP, et al. Efficacy and safety of subcutaneous tabalumab, a monoclonal antibody to B-cell activating factor, in patients with systemic lupus erythematosus: results from ILLUMINATE-2, a 52-week, phase III, multicentre, randomised, double-blind, placebo-controlled study. *Ann Rheum Dis.* 2016;75:332-340.
37. Isenberg D, Gordon C, Licu D, et al. Efficacy and safety of ataccept for prevention of flares in patients with moderate-to-severe systemic lupus erythematosus (SLE): 52-week data (APRIL-SLE randomised trial). *Ann Rheum Dis.* 2015;74:2006-2015.
38. Wu D, Li J, Xu D, et al. Telitacicept in patients with active systemic lupus erythematosus: results of a phase 2 b, randomised, double-blind, placebo-controlled trial. *Ann Rheum Dis.* 2024;83:475-487.
39. Furie R, Aroca G, Alvarez A, et al. A phase II randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of obinutuzumab or placebo in combination with mycophenolate mofetil in patients with active class III or IV lupus nephritis [abstract]. *Arthritis Rheumatol.* 2019;71(Suppl 10).
40. Mysler EF, Spindler AJ, Guzman R, et al. Efficacy and safety of ocrelizumab in active proliferative lupus nephritis: results from a randomized, double-blind, phase III study. *Arthritis Rheum.* 2013;65:2368-2379.
41. van Vollenhoven RF, Hahn BH, Tsokos GC, et al. Efficacy and safety of ustekinumab, an IL-12 and IL-23 inhibitor, in patients with active systemic lupus erythematosus: results of a multicentre, double-blind, phase 2, randomised, controlled study. *Lancet.* 2018;392:1330-1339.
42. Furie RA, Bruce IN, Dörner T, et al. Phase 2, randomized, placebo-controlled trial of dapirolizumab pegol in patients with moderate-to-severe active systemic lupus erythematosus. *Rheumatology.* 2021;60:5397-5407.
43. Clowse M, Isenberg D, Merrill J, et al. Dapirolizumab pegol demonstrated significant improvement in systemic lupus erythematosus disease activity: efficacy and safety results of a phase 3 trial [abstract]. *Arthritis Rheumatol.* 2024;76(Suppl 9). Available from: <https://acrabstracts.org/abstract/dapirolizumab-pegol-demonstrated-significant-improvement-in-systemic-lupus-erythematosus-disease-activity-efficacy-and-safety-results-of-a-phase-3-trial/> [cited 2025 Jul 12].
44. Furie RA, van Vollenhoven RF, Kalunian K, et al. Trial of anti-BDCA2 antibody litiflimab for systemic lupus erythematosus. *N Engl J Med.* 2022;387:894-904.
45. Merrill JT, Tanaka Y, D'Cruz D, et al. Efficacy and safety of upadacitinib or elsobrutinib alone or in combination for patients with systemic lupus erythematosus: a phase 2 randomized controlled trial. *Arthritis Rheumatol.* 2024;76:1518-1529.
46. Morand E, Pike M, Merrill JT, et al. Deucravacitinib, a tyrosine kinase 2 inhibitor, in systemic lupus erythematosus: a phase II, randomized, double-blind, placebo-controlled trial. *Arthritis Rheumatol.* 2023;75:242-252.
47. Chan J, Walters GD, Puri P, et al. Safety and efficacy of biological agents in the treatment of systemic lupus erythematosus (SLE). *BMC Rheumatol.* 2023;7:37.
48. Schett G, Mackensen A, Mougiakakos D. CAR T-cell therapy in autoimmune diseases. *Lancet.* 2023;402:2034-2044.
49. Schett G, Müller F, Taubmann J, et al. Advancements and challenges in CART cell therapy in autoimmune diseases. *Nat Rev Rheumatol.* 2024;20:531-544.
50. Mackensen A, Müller F, Mougiakakos D, et al. Anti-CD19 CAR T cell therapy for refractory systemic lupus erythematosus. *Nat Med.* 2022;28:2124-2132.
51. Hagen M, Bucci L, Böltz S, et al. BCMA-targeted T-cell-engager therapy for autoimmune disease. *N Engl J Med.* 2024;391:867-869.
52. Alexander T, Krönke J, Cheng Q, et al. Teclistamab-induced remission in refractory systemic lupus erythematosus. *N Engl J Med.* 2024;391:864-866.
53. Bucci L, Hagen M, Rothe T, et al. Bispecific T cell engager therapy for refractory rheumatoid arthritis. *Nat Med.* 2024;30:1593-1601.
54. Parodis I, Girard-Guyonvarc'h C, Arnaud L, et al. EULAR recommendations for the non-pharmacological management of systemic lupus erythematosus and systemic sclerosis. *Ann Rheum Dis.* 2024;83(6):720-729.
55. Saegusa K, Tsuchida Y, Komai T, et al. Advances in targeted therapy for systemic lupus erythematosus: current treatments and novel approaches. *Int J Mol Sci.* 2025;26(3):929.